Vibostolimab/Keytruda regimen did not improve overall survival compared to Tecentriq in extensive-stage SCLC patients. Median ...

Efti + KEYTRUDA combo shows strong efficacy for NSCLC patients in Immutep's phase 1 study. Read why IMMP stock may see upside ...

The company is paying China-based biotech LaNova Medicines $588 million for the same type of bispecific antibody drug that ...

In a move to safeguard the company’s dominant position in cancer, Merck said Thursday it will license a new cancer drug from ...

Merck & Co. is paying $588 million upfront to defend its Keytruda kingdom. The outlay, plus up to $2.7 billion in milestones, ...

Merck has licensed an early-stage cancer drug from a China-based biotech in an up to $3.3 billion deal, two months after a ...

Merck (MRK) announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use, or CHMP, adopted an opinion ...

Merck's undervalued stock presents growth opportunities with Keytruda and promising pipeline drugs, making it a Buy despite ...

Germany-based BioNTech got into the space before the gold rush that was unleashed in September by the news that Akeso and ...

As Merck prepares for its blockbuster immunotherapy Keytruda to face generic competition, it’s investing in a new cancer drug ...

The U.S. Food and Drug Administration approved the Keytruda combination in malignant pleural mesothelioma in September. Keytruda, a cancer drug that harnesses a patient's immune system to fight tumors ...

VEGF bispecifics. | Merck and BioNTech are buying Chinese biotechs to gain PD-(L)1/VEGF bispecifics. AstraZeneca's CEO argued ...